Fortis Group Advisors LLC Has $145,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Fortis Group Advisors LLC lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 65.5% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 872 shares of the company’s stock after selling 1,658 shares during the quarter. Fortis Group Advisors LLC’s holdings in Johnson & Johnson were worth $145,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. WealthTrak Capital Management LLC acquired a new stake in Johnson & Johnson during the 4th quarter worth $26,000. Mountain Hill Investment Partners Corp. acquired a new position in Johnson & Johnson during the fourth quarter valued at approximately $29,000. Conquis Financial LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter worth $33,000. Bernard Wealth Management Corp. bought a new position in shares of Johnson & Johnson during the 4th quarter worth about $36,000. Finally, Runnymede Capital Advisors Inc. purchased a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $38,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Down 1.1%

JNJ opened at $163.04 on Friday. The business’s 50-day moving average price is $154.10 and its 200-day moving average price is $154.84. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. The company has a market cap of $392.28 billion, a P/E ratio of 17.44, a P/E/G ratio of 2.21 and a beta of 0.41. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The firm had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter last year, the firm earned $2.82 EPS. The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. On average, equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 3.19%. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on JNJ. Guggenheim upped their target price on shares of Johnson & Johnson from $164.00 to $167.00 and gave the stock a “neutral” rating in a research report on Thursday. Benchmark upgraded shares of Johnson & Johnson to a “strong-buy” rating in a report on Thursday, April 24th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday. Finally, Bank of America lifted their price target on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a “neutral” rating in a research note on Thursday. Eleven investment analysts have rated the stock with a hold rating, nine have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $174.11.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.